TOP1 modulation during melanoma progression and in adaptative resistance to BRAF and MEK inhibitors-Reference-Cited by-同舟云学术

TOP1 modulation during melanoma progression and in adaptative resistance to BRAF and MEK inhibitors

Published:2021-11 Issue: Volume:173 Page:105911
ISSN:1043-6618
Container-title:Pharmacological Research
language:en
Short-container-title:Pharmacological Research

Author:

Oliveira Érica Aparecida de,Chauhan Jagat^ORCID,Silva Julia Rezende da,Carvalho Larissa Anastacio da Costa,Dias Diogo^ORCID,Carvalho Danielle Gonçalves de,Watanabe Luis Roberto Masao,Rebecca Vito W.,Mills Gordon,Lu Yiling,da Silva Aloisio Souza Felipe,Consolaro Márcia Edilaine Lopes,Herlyn Meenhard,Possik Patricia A.,Goding Colin R.,Maria-Engler Silvya Stuchi

Publisher

Elsevier BV

Subject

Pharmacology

Reference71 articles.

1. The genomic landscape of cutaneous melanoma;Zhang;Pigment Cell Melanoma Res.,2016

2. Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma;Menzies;Clin. Cancer Res.,2012

3. Mutations of the BRAF gene in human cancer;Davies;Nature,2002

4. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations;Flaherty;N. Engl. J. Med.,2012

5. Inhibition of mutated, activated BRAF in metastatic melanoma;Flaherty;N. Engl. J. Med.,2010

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. QUALITY BY DESIGN APPROACH FOR DEVELOPMENT AND OPTIMIZATION OF CHITOSAN-BASED FLOATING MICROSPHERES FOR TOPOTECAN HCl;International Journal of Applied Pharmaceutics;2023-11-07

2. Tumor Cell Resistance to the Inhibition of BRAF and MEK1/2;International Journal of Molecular Sciences;2023-10-02

3. Isovalerylspiramycin I inhibits proliferation, migration and invasion of osteosarcoma cells by targeting Topoisomerase 1 and suppressing the ataxia telangiectasia and Rad3‐related/checkpoint kinase 1 pathway;Clinical and Translational Discovery;2023-07-20

4. Venlafaxine, an anti-depressant drug, induces apoptosis in MV3 human melanoma cells through JNK1/2-Nur77 signaling pathway;Frontiers in Pharmacology;2023-01-04

5. Characterization of anticancer drug resistance by reverse-phase protein array: new targets and strategies;Expert Review of Proteomics;2022-02-01